Stifel Starts PhaseBio Pharmaceuticals Inc. (PHAS) at Buy

October 13, 2021 5:21 AM EDT Send to a Friend
Stifel analyst Annabel Samimy initiates coverage on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login